21948233 |
ALK mutations conferring differential resistance to structurally diverse ALK inhibitors
Lovly, CM,
Grütter, C,
Heynck, S,
Sos, ML,
Thomas, RK,
Peifer, M,
Balke-Want, H,
Heuckmann, JM,
Rauh, D,
Koker, M,
Weiss, J,
Pao, W,
Hölzel, M
|
Clin. Cancer Res. |
2011 |
18923525 |
Activating mutations in ALK provide a therapeutic target in neuroblastoma
Zozulya, S,
George, RE,
Gilliland, DG,
Morris, SW,
Luther, W,
London, WB,
Hanna, M,
Meyerson, M,
McGrady, P,
Sanda, T,
Gregor, VE,
Look, AT,
Zhang, J,
Fröhling, S,
Ahn, Y,
Diller, L,
Webb, TR,
Zhou, W,
Greulich, H,
Gray, NS,
Xue, L
|
Nature |
2008 |
21791641 |
A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors
Zheng, W,
Lindeman, N,
Capelletti, M,
Gray, NS,
Wong, KK,
Christensen, JG,
Ercan, D,
Jänne, PA,
Rodig, SJ,
Shimamura, T,
Nikiforow, S,
Weremowicz, S,
Sasaki, T,
Okuda, K,
Wilner, K,
Eck, MJ,
Butaney, M,
Stumpfova, M,
Yanagita, M,
Heon, S,
Ogino, A,
Xiao, Y,
Marcoux, JP,
Koivunen, J,
Lathan, C,
Du, J
|
Cancer Res. |
2011 |